Levin M L
Division of Nephrology/Hypertension, Northwestern University Medical School, Chicago, USA.
J Crit Illn. 1994 Oct;9(10):911-2, 915.
The kidneys are the primary site of aminoglycoside clearance; any factor that permits renal parenchymal accumulation increases the risk of aminoglycoside nephrotoxicity. The most common underlying cause is excessive aminoglycoside administration (especially in women or elderly patients). To minimize the risk of nephrotoxicity, select loading and maintenance aminoglycoside dosages based on estimated creatinine clearance. Also, monitor peak and trough serum aminoglycoside levels, replenish volume, and correct potassium and magnesium abnormalities. If possible, avoid giving aminoglycosides to patients with hepatic dysfunction or to those receiving other nephrotoxic drugs or radiocontrast agents.
肾脏是氨基糖苷类药物清除的主要部位;任何允许肾实质蓄积的因素都会增加氨基糖苷类药物肾毒性的风险。最常见的潜在原因是氨基糖苷类药物给药过量(尤其是在女性或老年患者中)。为将肾毒性风险降至最低,根据估计的肌酐清除率选择氨基糖苷类药物的负荷剂量和维持剂量。此外,监测血清氨基糖苷类药物的峰浓度和谷浓度,补充血容量,并纠正钾和镁异常。如果可能,避免给肝功能不全的患者或正在接受其他肾毒性药物或放射性造影剂的患者使用氨基糖苷类药物。